Showing 81-100 of 498 for: Cochrane Systematic Reviews > Neurologic 
- Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Cochrane Systematic Reviews, 24-Oct-2018
This is an updated version of the Cochrane Review previously published in 2016. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.
- Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Cochrane Systematic Reviews, 18-Jul-2019
This is an update of a Cochrane Review first published in 2002 and last updated in 2017. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.
- Carbamazepine versus valproate monotherapy for epilepsy
Cochrane Systematic Reviews, 24-Jul-2000
Carbamazepine and valproate are drugs of first choice for epilepsy. Despite the lack of hard evidence from individual randomized controlled trials, there is strong clinical belief that valproate is the drug of choice for generalized epilepsies and carbama
- Care delivery and self management strategies for adults with epilepsy
Cochrane Systematic Reviews, 4-Feb-2016
Researchers have criticised epilepsy care for adults for its lack of impact, stimulating the development of various service models and strategies to respond to perceived inadequacies.
- Care delivery and self‐management strategies for children with epilepsy
Cochrane Systematic Reviews, 1-Mar-2018
In response to criticism that epilepsy care for children has little impact, healthcare professionals and administrators have developed various service models and strategies to address perceived inadequacies.
- Carnitine for fatigue in multiple sclerosis
Cochrane Systematic Reviews, 17-Apr-2012
Fatigue is reported to occur in up to 92% of patients with multiple sclerosis (MS) and has been described as the most debilitating of all MS symptoms by 28% to 40% of MS patients.
- Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease
Cochrane Systematic Reviews, 12-Nov-2008
As Parkinson's disease progresses the control of motor symptoms often requires the addition of other drugs to levodopa. The principle aim of COMT inhibitor therapy is to increase the duration of effect of each levodopa dose and thus reduce the time patien
- Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease
Cochrane Systematic Reviews, 12-Nov-2008
As Parkinson's disease progresses the control of the symptoms often requires the addition of other drugs to levodopa. The principle aim of COMT inhibitor therapy is to increase the duration of effect of the levodopa dose and thus reduce the time patients
- Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders
Cochrane Systematic Reviews, 6-Nov-2013
Management of the neurogenic bladder has the primary objectives of maintaining continence, ensuring low bladder pressure (to avoid renal damage) and avoiding or minimising infection. Options include intermittent urethral catheterisation, indwelling urethr
- Central action beta‐blockers versus placebo for neuroleptic‐induced acute akathisia
Cochrane Systematic Reviews, 18-Oct-2004
Neuroleptic-induced akathisia is a common, distressing early-onset adverse effect of neuroleptic drugs. It has been associated with poor treatment compliance and an increased risk of relapse.
- Cervico‐thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome
Cochrane Systematic Reviews, 2-Sep-2013
This review is an update of a review first published in Issue 2, 2003, which was substantially updated in Issue 7, 2010. The concept that many neuropathic pain syndromes (traditionally this definition would include complex regional pain syndromes (CRPS))
- Chemotherapy for high‐grade glioma
Cochrane Systematic Reviews, 21-Oct-2002
Trials on the effect of systemic chemotherapy on survival and recurrence in adults with high-grade glioma have had inconclusive results. We undertook a systematic review and meta-analysis to assess the effects of such treatment on survival and recurrence.
- Chinese herbal medicine for diabetic peripheral neuropathy
Cochrane Systematic Reviews, 4-Oct-2013
Chinese herbal medicine is frequently used for treating diabetic peripheral neuropathy in China. Many controlled trials have been undertaken to investigate its efficacy.
- Cholinergic medication for antipsychotic‐induced tardive dyskinesia
Cochrane Systematic Reviews, 19-Mar-2018
Tardive dyskinesia (TD) remains a troublesome adverse effect of conventional antipsychotic (neuroleptic) medication. It has been proposed that TD could have a component of central cholinergic deficiency. Cholinergic drugs have been used to treat TD.
- Cholinesterase inhibitors for Alzheimer's disease
Cochrane Systematic Reviews, 18-Mar-2016
** This review is awaiting update with a new protocol. The methods used for the review were acceptable when the review was published but do not meet contemporary standards, and the review is also considerably out of date. Therefore, readers should note th
- Cholinesterase inhibitors for delirium
Cochrane Systematic Reviews, 23-Jan-2008
Delirium is now the preferred term to describe acute confusional states. It is experienced by 10 to 30% of all hospital inpatients. Delirium is potentially reversible and is related to several adverse outcomes, including increased hospital length of stay,
- Cholinesterase inhibitors for dementia with Lewy bodies
Cochrane Systematic Reviews, 27-Apr-2008
Dementia with Lewy bodies (DLB) was first described in 1983, and clinical diagnostic criteria were published in the early to mid 1990s. It has been suggested DLB may account for up to 15-25% of cases of dementia among people aged over 65, although autopsy
- Cholinesterase inhibitors for Parkinson's disease dementia
Cochrane Systematic Reviews, 5-May-2008
The loss of cholinergic, dopaminergic and noradrenergic innervations seen in Parkinson's Disease Dementia (PDD) suggest a potential role for cholinesterase inhibitors. Concerns have been expressed about a theoretical worsening of Parkinson's disease relat
- Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease
Cochrane Systematic Reviews, 19-Jul-2004
Amyotrophic lateral sclerosis, also known as motor neuron disease, is a fatal neuromuscular disease characterized by progressive muscle weakness resulting in paralysis. It might be treated with ciliary neurotrophic factor. This is an updated review. An up
- Clobazam add‐on therapy for drug‐resistant epilepsy
Cochrane Systematic Reviews, 22-Oct-2019
Epilepsy affects approximately 1% of the population, with up to 30% of patients continuing to have seizures, despite antiepileptic drug treatment. Clobazam is a 1,5-benzodiazepine and is commonly used as an add-on treatment for drug-resistant epilepsy. Th
